Columbia neuroscientists have identified a genetic mutation that fends off Alzheimer's in people at high risk and could lead to a new way to protect people from the disease.
ADScreen, a speech-processing algorithm developed at Columbia Nursing, is now being tested in a clinical trial to see if it can help health care workers identify patients with Alzheimer's earlier.
Lecanemab, marketed as Leqembi, is the first drug for Alzheimer’s disease to receive approval on the basis of clinically slowing the progression of Alzheimer’s disease.
Attending a high school with a high number of teachers with graduate training was the clearest predictor of the impact of school quality on late-life cognition, researchers found.